Rob Jones
Chief Investigator
Early Phase Lead in Wales
Speciality Lead for Cancer in Wales
Reader and Consultant in Medical Oncology

Lesley Radley
Public Partner
FAKTION; A phase 1b/randomised placebo controlled phase II trial of Fulvestrant +/- (AKT inhibition) in patients with incurable breast cancer

NIHR/CRUK Combinations Alliance National Portfolio Investigator Led Trial

Cardiff University and Velindre Chief Investigator; Rob Jones
Coordinated by Cardiff University Centre for Trials Research
PPI Lesley Radley
Sponsored by Velindre NHS Trust, Cardiff
Circulating tumour DNA translational research being carried out on by Cardiff University Clinical Research Fellow in All Wales Genetics Laboratory
Data from this Trial accepted as an Oral presentation at ASCO June 2019 and being submitted to The Lancet Oncology for publication
Recruitment into the Phase 2 part of FAKTION Trial took place for over 3 years (Phase 1b approximately 12 months)
FAKTION Trial; Progression Free Survival by Treatment

KM curves for PFS by treatment

Number at risk
Fulv/Placebo 71
Fulv/AZD5363 69

Months from Randomisation
Progression Free Survival (%)
### FAKTION outcome data

<table>
<thead>
<tr>
<th></th>
<th>Fulvestrant with Placebo</th>
<th>Fulvestrant with Capavasetrib</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Response Rate</strong></td>
<td>12%</td>
<td>41%</td>
</tr>
<tr>
<td>% of patients who had a</td>
<td></td>
<td></td>
</tr>
<tr>
<td>significant Shrinkage</td>
<td></td>
<td></td>
</tr>
<tr>
<td>in their Cancer</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Progression Free</strong></td>
<td>4.8 months</td>
<td>10.3 months</td>
</tr>
<tr>
<td><strong>Survival</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Average time patients</td>
<td></td>
<td></td>
</tr>
<tr>
<td>cancer was controlled</td>
<td></td>
<td></td>
</tr>
<tr>
<td>on treatment</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Overall Survival</strong></td>
<td>20 months</td>
<td>26 months</td>
</tr>
<tr>
<td>How long patients</td>
<td></td>
<td></td>
</tr>
<tr>
<td>lived for</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
## Comparison of PALOMA and FAKTION Trial data

<table>
<thead>
<tr>
<th></th>
<th><strong>PALOMA</strong></th>
<th><strong>FAKTION</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(leading to Pablociclib</td>
<td></td>
</tr>
<tr>
<td></td>
<td>becoming SOC)</td>
<td></td>
</tr>
<tr>
<td>Progression Free Survival</td>
<td><strong>Hazard Ratio 0.58</strong></td>
<td><strong>Hazard Ratio 0.57</strong></td>
</tr>
<tr>
<td>advantage in Treatment group</td>
<td>(24.8 vs 14.5)</td>
<td>(10.32 vs 4.8)</td>
</tr>
<tr>
<td>Overall Survival advantage</td>
<td><strong>6.9 months</strong></td>
<td><strong>6.02 months</strong></td>
</tr>
<tr>
<td>in Treatment group</td>
<td>(34.9 VS 28)</td>
<td>(26.02 vs 20)</td>
</tr>
</tbody>
</table>
Incidence of different Cancer types

- Breast
- Prostate
- Lung
- Bowel
- Melanoma Skin Cancer
- Non-Hodgkin Lymphoma
- Kidney
- Head and Neck
- Brain, Other CNS & Intracranial Tumours
- Bladder
- Pancreas
- Leukaemia
- Oesophagus
- Uterus
- Cancer of Unknown Primary
- Ovary
- Stomach
- Liver
- Myeloma
- Thyroid
- Other sites
FAKTION Summary

• FAKTION is a UK wide National Portfolio trial led from Cardiff
• The results are high impact (Oral Presentation ASCO 2019 and manuscript in being submitted to The Lancet Oncology)
• One of first trials to have significant PPI involvement
• Protocol currently in development with AZ to confirm findings of Phase 2 with an international Phase 3
• Could lead to a change in the SOC for tens of millions of Breast Cancer patients